Trial · NCT01007448
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Tumor Response (Complete Response [CR], Clinical Complete Response [CCR], and Partial Response [PR]) in up to 5 Index Lesions as Determined by Investigator's Composite Assessment (CA) of Index Lesion Disease Severity | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Tumor Response of CR, CCR, PR, SD, and PD as Determined by Physician's Global Assessment (PGA) of Clinical Condition | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants With Tumor Response of CR, CCR, PR, SD, and PD as Determined Percent Body Surface Area (BSA) Involvement | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population). | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Duration of Tumor Response (CR, CCR, or PR) as Determined by Investigator's CA of Index Lesion Disease Severity | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with the best overall response of evaluable CR, CCR, and PR data for CA of index lesion disease severity. | days | MEAN |
| SECONDARY | Duration of Tumor Response (CR, CCR, or PR) as Determined by PGA of Clinical Condition | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with the best overall response of evaluable CR, CCR, and PR data for PGA of clinical condition. | days | MEAN |
| SECONDARY | Duration of Tumor Response (CR, CCR, or PR) as Determined by Percent BSA Involvement | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with the best overall response of evaluable CR, CCR, and PR data for percent of BSA involvement. | days | MEAN |
| SECONDARY | Time to Tumor Response (CR, CCR, or PR) as Determined by CA of Index Lesion Disease Severity | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with the best overall response of evaluable CR, CCR, and PR data for CA of index lesion disease severity. | days | MEAN |
| SECONDARY | Time to Tumor Response (CR, CCR, or PR) as Determined by PGA of Clinical Condition | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with the best overall response of evaluable CR, CCR, and PR data for PGA of clinical condition. | days | MEAN |
| SECONDARY | Time to Tumor Response (CR, CCR, or PR) as Determined by Percent BSA Involvement | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with the best overall response of evaluable CR, CCR, and PR data for percent of BSA involvement. | days | MEAN |
| SECONDARY | Time to Tumor Progression as Determined by CA of Index Lesion Disease Severity | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with evaluable PD data for CA of index lesion disease severity. | days | MEAN |
| SECONDARY | Time to Tumor Progression as Determined by PGA of Clinical Condition | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with progression. | days | MEAN |
| SECONDARY | Time to Tumor Progression as Determined by Percent BSA Involvement | Baseline up to Week 24 | Participants who received at least 1 dose of study drug (Full Analysis Population) and with progression. | days | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01007448/outcomes